Moclobemide versus fluoxetine for a major depressive episode
| Autor: | Christine Reynaert, L. Haazen, J. Mirel, M. Parent, Pascal Janne |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Low dosage Adolescent Moclobemide Drug Administration Schedule Double-Blind Method Oral administration Internal medicine Fluoxetine medicine Humans Pharmacology (medical) Sexual Dysfunctions Psychological Major depressive episode Adverse effect Biological Psychiatry Depression (differential diagnoses) Aged Pharmacology Depressive Disorder Dose-Response Relationship Drug business.industry Middle Aged Antidepressive Agents Psychiatry and Mental health Sexual dysfunction Neurology Tolerability Anesthesia Benzamides Female Neurology (clinical) medicine.symptom business Psychology Reuptake inhibitor medicine.drug |
| Zdroj: | Psychopharmacology. 118:183-187 |
| ISSN: | 1432-2072 0033-3158 |
| Popis: | The efficacy and tolerability of moclobemide (300-600 mg daily) and fluoxetine (20-40 mg daily) were compared in a 6-week, double-blind study of 65 inpatients and 34 outpatients suffering from major depressive episodes (DSM III-R). No statistically significant differences between the two treatment groups were noted regarding efficacy (HDRS, CGI) or safety (adverse events, laboratory examination, vital signs). Moclobemide (300-600 mg daily) and fluoxetine (20-40 mg daily) would thus appear to be comparable both in antidepressant efficacy and tolerability. Doubling the low dosage in non-responders after 3 weeks resulted in a statistically significant improvement of CGI in the moclobemide group by comparison with the fluoxetine group at study end, suggesting that 600 mg moclobemide/day can still improve the patient's condition, while 40 mg fluoxetine/day does not. Sexual dysfunction was reported in two patients taking fluoxetine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink